DE602007009957D1 - Neue kristalline form von lamivudin - Google Patents

Neue kristalline form von lamivudin

Info

Publication number
DE602007009957D1
DE602007009957D1 DE602007009957T DE602007009957T DE602007009957D1 DE 602007009957 D1 DE602007009957 D1 DE 602007009957D1 DE 602007009957 T DE602007009957 T DE 602007009957T DE 602007009957 T DE602007009957 T DE 602007009957T DE 602007009957 D1 DE602007009957 D1 DE 602007009957D1
Authority
DE
Germany
Prior art keywords
new
disclosed
pharmaceutical composition
same
lamivudin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007009957T
Other languages
German (de)
English (en)
Inventor
Girij Pal Singh
Dhananjai Srivastava
Manmeet Brijkishore Saini
Pritesh Rameshbhai Upadhyay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lupin Ltd
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of DE602007009957D1 publication Critical patent/DE602007009957D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE602007009957T 2006-04-18 2007-02-09 Neue kristalline form von lamivudin Active DE602007009957D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN347KO2006 2006-04-18
PCT/IN2007/000047 WO2007119248A1 (en) 2006-04-18 2007-02-09 A novel crystalline form of lamivudine

Publications (1)

Publication Number Publication Date
DE602007009957D1 true DE602007009957D1 (de) 2010-12-02

Family

ID=37969898

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007009957T Active DE602007009957D1 (de) 2006-04-18 2007-02-09 Neue kristalline form von lamivudin

Country Status (10)

Country Link
US (1) US8158607B2 (https=)
EP (1) EP2007758B1 (https=)
JP (1) JP5184511B2 (https=)
AT (1) ATE485292T1 (https=)
AU (1) AU2007237818B2 (https=)
CA (1) CA2649796A1 (https=)
DE (1) DE602007009957D1 (https=)
ES (1) ES2357159T3 (https=)
WO (1) WO2007119248A1 (https=)
ZA (1) ZA200809820B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009037538A2 (en) * 2007-09-17 2009-03-26 Aurobindo Pharma Ltd Process for the preparation of lamivudine form i
WO2009069014A1 (en) * 2007-11-29 2009-06-04 Ranbaxy Laboratories Limited Amorphous lamivudine and its preparation
AU2008331168A1 (en) * 2007-11-29 2009-06-04 Ranbaxy Laboratories Limited Crystalline form I of lamivudine and its preparation
WO2009116055A1 (en) * 2008-03-17 2009-09-24 Lupin Limited Lamivudine : zidovudine : water 1 : 1 : 1 cocrystal
WO2009127996A1 (en) * 2008-04-17 2009-10-22 Ranbaxy Laboratories Limited Novel crystalline form of lamivudine
US8536151B2 (en) 2008-09-01 2013-09-17 Hetero Research Foundation Process for preparing lamivudine polymorph form
US8481554B2 (en) 2009-05-27 2013-07-09 Hetero Research Foundation Solid oral dosage forms of lamivudine
ES2540074T3 (es) 2009-10-14 2015-07-08 Mylan Laboratories Limited Proceso para la preparación de lamivudina y nuevas sales en la fabricación de la misma
EP2536715A1 (en) 2010-02-12 2012-12-26 Merck Sharp & Dohme Corp. Preparation of lamivudine form i
WO2013168066A1 (en) 2012-05-05 2013-11-14 Lupin Limited An improved process for the manufacture of lamivudine form i.
EP2953945A2 (en) * 2013-02-07 2015-12-16 Tobira Therapeutics, Inc. Lamivudine salts

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
WO2003027106A1 (en) * 2001-09-25 2003-04-03 Cadila Healthcar Limited Process for the preparation of crystalline polymorph ii of lamivudine

Also Published As

Publication number Publication date
JP2009534373A (ja) 2009-09-24
CA2649796A1 (en) 2007-10-25
WO2007119248A1 (en) 2007-10-25
ES2357159T3 (es) 2011-04-19
ZA200809820B (en) 2010-02-24
EP2007758B1 (en) 2010-10-20
AU2007237818B2 (en) 2012-09-27
JP5184511B2 (ja) 2013-04-17
ATE485292T1 (de) 2010-11-15
EP2007758A1 (en) 2008-12-31
US20090281053A1 (en) 2009-11-12
US8158607B2 (en) 2012-04-17
AU2007237818A1 (en) 2007-10-25

Similar Documents

Publication Publication Date Title
ATE485292T1 (de) Neue kristalline form von lamivudin
MY167135A (en) Fused heterocyclic derivatives and methods of use
MX2009006764A (es) Pirimidinonas biciclicas y usos de la misma.
NO20081315L (no) Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
UA86614C2 (ru) Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
EA200802203A1 (ru) Дикетопиперазиновые и пиперидиновые производные в качестве противовирусных агентов
JO3271B1 (ar) مشتقات الكوينولين المضادة للجراثيم
EA201101671A1 (ru) Замещенные производные аминопропионовой кислоты в качестве ингибиторов неприлизина
WO2009123776A3 (en) Antiviral drugs for treatment of arenavirus infection
CL2007003609A1 (es) Compuestos derivados de dihidropiridinas sustituidas; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; proceso para producir la composicion farmaceutica; y uso en el tratamiento de una enfermedad mejorada con la inhibicion
WO2009091374A3 (en) Fused heterocyclic derivatives and methods of use as c-met inhibitors
GEP20156366B (en) Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
CL2011000716A1 (es) Formas cristalinas 1 6 de (s)-isopropil-2-(((s)-(((2r.3r.4r.5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1(2h)-il)-4-fluoro-3-hidroxi-4-metil tetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato; composicion y combinacion farmaceutica; y su uso para tratar una infeccion por el virus de la hepatitis c.
CL2008003067A1 (es) Compuesto 2-[3-(2,2-difluoro-benzo[1,3]dioxol-5-ilamino)-5-(2,6-dimetil-piridin-4-il)-[1,2,4]triazol-1-il]-n-etil-acetamida, modulador de receptores nicotinicos alfa-7; proceso de preparacion; composicion farmaceutica y su proceso de preparacion; y su uso en el tratamiento de trastornos psicoticos, intelectuales, inflamatorios.
ME01456B (me) Fumaratna so (alfa s, beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoksi-alfa-1-naftalenil-beta-fenil-3-kinolinetanola
EA200970534A1 (ru) Антибактериальные производные хинолина
WO2006124861A3 (en) Benzofuran compounds
CL2009001137A1 (es) Compuestos derivados de cicloheptanocarboniloxi-1-azonia-biciclo[2.2.2]-octano, moduladores de receptores muscarinicos; composiciones farmaceuticas; proceso de preparacion de dicha composicion; y uso en el tratamiento de una enfermedad pulmonar obstructiva cronica.
WO2009042094A3 (en) Hiv protease inhibitors
MX2009007040A (es) Derivados de mononitrato de isosorbida para el tratamiento de hipertension ocular.
CL2007003318A1 (es) Compuestos derivados de 4,5-difenil-pirrol-2-carboxamida; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento o la prevencion de enfermedades tales como sindrome de abstinencia a una sustancia, t
JO2725B1 (en) Quinoline antibacterial derivatives
EA200970536A1 (ru) Антибактериальные хинолиновые производные
JO2685B1 (en) Quinoline antibacterial derivatives
MX2010013978A (es) Derivados de 5-(4-metanosulfonilfenil)tiazol para el tratamiento de enfermedades inflamatorias agudas y cronicas.